New hope for breast cancer patients when first treatment fails
NCT ID NCT05675579
Summary
This study is testing whether a combination of two drugs, sacituzumab govitecan and pembrolizumab, can help control early-stage triple-negative breast cancer when given before surgery. It is for patients whose cancer did not shrink after their initial round of chemotherapy and immunotherapy. The main goal is to see if this new approach can eliminate or greatly reduce the cancer found at surgery.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.